Evidence-reviewed papers with scope and limitations Β· Updated November 08, 2026
How to read these entries: each item links to a full BGPT evidence review with quality scores, limitations, and proposed follow-up experiments. Findings are stated with their strength of evidence β nothing here is overstated.
In primary endothelial cells, the fusion oncogene triggered hypertranscription, DNA damage, and senescence β but all data are mouse in vitro, and the proposed ATR/PARP therapeutic window remains untested pharmacologically.
Strong causal chain (rescue, epistasis, deposited datasets) shows KIF20AβSMARCA4 supports mitochondrial identity in TNBC stem cells, though validation rests on immunodeficient xenografts and a limited cell-line panel.
Clonal assays across three CRC lines showed stem-like fractions varying ~20-fold (SW1222 ~20β30% vs HCT116 nearly all), so conclusions rest on few lines and primary-tumor applicability is proposed but not demonstrated.
An NRF2βFACT feedback loop was traced mechanistically in HCC with a Curaxin combination rationale, but the cohort was small (n=16 HBV-only pairs) and used immunodeficient mice without immune context.
A 252-patient tissue-microarray study with orthotopic mouse validation supports NCAMβFGFR signaling as a tumor-selective drug target, but therapeutic validation is murine-only and one author discloses a consultation.
A 2025 narrative review maps how exosomal cargo bidirectionally controls ferroptosis across TME cell types β mechanistically rich but preclinical, non-systematic, and with heterogeneous cited exosome-isolation methods.
The non-RGD binding mode may avoid cilengitide's failed agonism paradox, but the review notes Ξ²-subunit compensation among Ξ±V integrins as an unresolved risk given repeated GBM trial failures.
A ~1,000-word editor summary of five preclinical studies with no new data, abstract, or methods; two of five contributions target tumor cells or imaging rather than the microenvironment itself.
Dual siRNA knockdown reduced viability to ~33β48% in two cell lines, supporting HSF1 as a candidate target β but the abstract lacks replicate counts, rescue experiments, and normal-cell toxicity data.
Mimic transfection reduced tumorsphere formation and induced apoptosis, but with ~8.36-fold supraphysiological overexpression, a single laboratory line, and no direct 3'UTR target validation.
A consolidation review maps EMT pathways and ncRNA axes in gallbladder cancer, but E-cadherin loss varies >6-fold across cohorts (11.9β80%), so clinical marker claims are assay-driven and not standardized.
Full reviews include quality-scored metrics, key insights, and proposed follow-up experiments at bgpt.pro
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.
Explore by Goal
Trending